Evidence map›Paper›PMID 26322864›Full record

ArticleACS chemical biology2015

Selective Targeting of Cells via Bispecific Molecules That Exploit Coexpression of Two Intracellular Proteins.

Bryan M Dunyak, Robert L Nakamura, Alan D Frankel, Jason E Gestwicki

Open access · greenAbstract readLetter
In one paragraph

Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bryan M Dunyak
Robert L NakamuraAdvanced Genetic Systems , San Francisco, California 94158, United States.
Alan D Frankel
Jason E Gestwicki
Advanced Genetic Systems (United States) · US

Funding

X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANKEL, ALAN D · 2007 to 2018
$48.8M
Natural Product-Inspired Method for Enhancing HIV Protease InhibitorsR21AI098431 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GESTWICKI, JASON E · 2012 to 2013
$424k
Mechanistic Studies of a Novel Small Molecule HIV InhibitorR41GM115250 · NIGMS · ADVANCED GENETIC SYSTEMS, INC. · PI NAKAMURA, ROBERT · 2015 to 2015
$277k
NIAID NIH HHS AI098431NIAID NIH HHS R21 AI098431NIGMS NIH HHS GM082250NIGMS NIH HHS GM115250NIGMS NIH HHS P50 GM082250
6 · The paper itself

Abstract

In drug discovery, small molecules must often discriminate between healthy and diseased cells. This feat is usually accomplished by binding to a protein that is preferentially expressed in the target cell or on its surface. However, in many cases, the expression of an individual protein may not generate sufficient cyto-selectivity. Here, we demonstrate that bispecific molecules can better discriminate between similar cell types by exploiting their simultaneous affinity for two proteins. Inspired by the natural product FK506, we designed molecules that have affinity for both FKBP12 and HIV protease. Using cell-based reporters and live virus assays, we observed that these compounds preferentially accumulated in cells that express both targets, mimicking an infected lymphocyte. Treatment with FKBP12 inhibitors reversed this partitioning, while overexpression of FKBP12 protein further promoted it. The partitioning into the target cell type could be tuned by controlling the properties of the linker and the affinities for the two proteins. These results show that bispecific molecules create significantly better potential for cyto-selectivity, which might be especially important in the development of safe and effective antivirals and anticancer compounds.

Indexed as

Drug Delivery SystemsDrug DesignGene Expression RegulationAntibodies, BispecificFlow CytometryHIV ProteaseHumansMolecular StructureTacrolimus Binding Protein 1AAntibodies, BispecificHIV ProteaseTacrolimus Binding Protein 1A

Identifiers

PMID26322864
PMCPMC4714926
OpenAlexW2408829075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.